article thumbnail

Stämm Biotech raises $17M for its next-generation, 3D printed bioreactor

TechCrunch

Stämm Biotech , founded in 2014, is developing a desktop-sized bioreactor that looks pretty different from the tanks, tubes and knobs traditionally seen in industrial or even benchtop bioreactors. Image Credits: Stämm Biotech. Image Credits: Stämm Biotech. The movement itself acts as the stirring motion.

Biotech 226
article thumbnail

Unicorn Bio is building the hardware to scale cultivated meat from lab to table

TechCrunch

“Using this legacy hardware to cultivate meat requires one to reengineer the cells. Our approach and core conviction is that it is actually easier, and ultimately better, to design new hardware systems aimed to foster the growth around the cells, rather than trying to fit these cells to existing engineering systems.”

Hardware 233
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The 10 Biggest Rounds Of February: Saronic And NinjaOne Lead Big Month

Crunchbase News

Lambda , $480M, artificial intelligence: Lambda, which offers cloud computing services and hardware for training artificial intelligence software, raised a $480 million Series D co-led by Andra Capital and SGW. Eikon Therapeutics , $351M, biotech: Eikon Therapeutics raised one of the biggest biotech rounds thus far in 2025.

article thumbnail

AI, Data Center And Energy Startups Get Large Capital Infusion In October

Crunchbase News

Those 50 companies that raised large rounds in October ranged across many sectors, including AI, data centers, nuclear energy, biotech, semiconductors, fintech, space and robotics. The second-largest sector, healthcare and biotech, raised around $5.6 Still, AI led But AI was still by far the leading sector, with $12.2

article thumbnail

TechCrunch+ roundup: Non-dilutive biotech capital, long-term angel investing, WayRay’s $80M pitch deck

TechCrunch

3 tips for biotech startups seeking non-dilutive capital to weather the downturn. Most biotech founders who are looking to raise in this environment assume that dilutive capital is their only option, but that’s short-sighted, writes James Coates, Health and Human Performance principal at Decisive Point.

Biotech 210
article thumbnail

The Case For Revenue-Focused Platforms In The Life Sciences

Crunchbase News

By Caleb Appleton Having invested in the biotech space since before it had a name, Ive seen life sciences investors steer founders toward a therapeutics pipeline in hopes of securing the payout of a winning drug or medical device.

Biotech 115
article thumbnail

Glyphic Biotechnologies raises $6M to accelerate protein sequencing by orders of magnitude

TechCrunch

The whole human proteome may be free to browse thanks to DeepMind , but at the bleeding edge of biotech new proteins are made and tested every day, a complex and time-consuming process. Going from service to hardware sales and support is the current roadmap. Berkeley has a big new biotech incubator in Bakar Labs.

Biotech 249